Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study

[1]  A. Lotery,et al.  Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set , 2017, Eye.

[2]  A. Tsujikawa,et al.  INCIDENCE AND CAUSES OF VISION LOSS DURING AFLIBERCEPT TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: One-Year Follow-up , 2017, Retina.

[3]  M. Kassiou,et al.  Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination† †The authors declare no competing interests. , 2016, MedChemComm.

[4]  V. Chong.  Ranibizumab for the treatment of wet AMD: a summary of real-world studies , 2016, Eye.

[5]  Glenn J Jaffe,et al.  Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials. , 2016, Ophthalmology.

[6]  H. Kim,et al.  Response of Pigment Epithelial Detachment to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration. , 2016, American journal of ophthalmology.

[7]  Q. Nguyen,et al.  Aflibercept for neovascular age-related macular degeneration. , 2016, The Cochrane database of systematic reviews.

[8]  Bianca S. Gerendas,et al.  Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. , 2016, JAMA ophthalmology.

[9]  V. Chong.  Ranibizumab for the treatment of wet AMD: a summary of real-world studies , 2016, Eye.

[10]  U. Schmidt-Erfurth,et al.  A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration , 2016, Progress in Retinal and Eye Research.

[11]  Alberto Ferreira,et al.  Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA , 2015, PloS one.

[12]  Christian Simader,et al.  Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. , 2015, Ophthalmology.

[13]  Ivana K. Kim,et al.  Clinical Medicine Age-related Macular Degeneration: Advances in Management and Diagnosis , 2022 .

[14]  Daniel M Miller,et al.  Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration. , 2015, Ophthalmic surgery, lasers & imaging retina.

[15]  Christian Simader,et al.  Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. , 2014, Ophthalmology.

[16]  S. Sivaprasad,et al.  Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. , 2013, American journal of ophthalmology.

[17]  M. Larsen,et al.  Predictors of 1‐year visual outcome in neovascular age‐related macular degeneration following intravitreal ranibizumab treatment , 2013, Acta ophthalmologica.

[18]  M. Mandai,et al.  Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[19]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[20]  J. Kim,et al.  Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. , 2012, American journal of ophthalmology.

[21]  N. Eter,et al.  High-resolution optical coherence tomography of subpigment epithelial structures in patients with pigment epithelium detachment secondary to age-related macular degeneration , 2012, British Journal of Ophthalmology.

[22]  E. Souied,et al.  Cystoid macular degeneration in exudative age-related macular degeneration. , 2011, American journal of ophthalmology.

[23]  R. Guymer,et al.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.

[24]  Masayuki Hata,et al.  The significance of external limiting membrane status for visual acuity in age-related macular degeneration. , 2010, American journal of ophthalmology.

[25]  U. Schmidt-Erfurth,et al.  Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration , 2009, British Journal of Ophthalmology.

[26]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[27]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[28]  A. Bird,et al.  Pigment epithelial detachment in the elderly , 2002, Graefe's Archive for Clinical and Experimental Ophthalmology.

[29]  A. Bird,et al.  Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. , 2002, Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie.

[30]  D. Barclay,et al.  One-year follow-up , 1975 .